A Case-Based Exploration of CAR T-Cell Therapy for Multiple Myeloma — Where We Are, Where We’re Going

Faculty

Sarah M Larson

MD

UCLA Health Santa Monica Cancer Care, Santa Monica, California

Hematologic Malignancy

Faculty

Shambavi D Richard

MD

Ruttenberg Treatment Center at The Mount Sinai Hospital, New York, New York

Internal Medicine, Cancer (Oncology), Hematology-Oncology

Faculty

Peter Voorhees

MD

Wake Forest University School of Medicine, Charlotte, North Carolina

Professor of Medicine

Atrium Health/Levine Cancer Institute, Charlotte, North Carolina

Chief, Plasma Cell Disorders Division

Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte, North Carolina

Associate Director of Clinical Research

Additional faculty to be announced.

Join us on Friday, December 11^th from 11:30 AM to 1:30 PM central time (12:30 PM to 2:30 PM eastern time).

MODULE 1: Current Use of BCMA-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

MODULE 2: Tolerability Considerations with BCMA-Targeted CAR T-Cell Therapy

MODULE 3: Other Novel Anti-BCMA CAR T-Cell Platforms Undergoing Investigation for MM

MODULE 4: Future Role of GPRC5D-Targeted CAR T-Cell Therapy in the Management of MM

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Understand the mechanism of action of B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy for MM, and appreciate the similarities and differences among currently available and investigational agents in this class.
• Develop an understanding of the current clinical research database with FDA-approved BCMA-directed CAR T-cell therapy platforms in the management of relapsed/refractory MM in order to optimally integrate this novel therapeutic strategy into current treatment algorithms.
• Appreciate the scientific justification for the development of next-generation BCMA-directed CAR T-cell approaches, and appraise available research findings and ongoing efforts attempting to definitively establish the efficacy and safety of these agents.
• Review the biological rationale for and published research findings with CAR T-cell therapy targeting GPRC5D (G protein-coupled receptor class C group 5 member D) in MM, and evaluate the potential role of this therapeutic strategy.
• Understand the pathophysiology of cytokine release syndrome and neurologic toxicity associated with CAR T-cell therapy for MM, and develop strategies to identify and manage these side effects.
• Recognize the spectrum, frequency and severity of other adverse events, such as secondary hematologic cancer, infections and cytopenias, associated with CAR T-cell therapy used in the care of patients with MM, and consider recommended approaches to prevent, ameliorate and manage these toxicities.
• Recall available data with novel CAR T-cell therapy-based strategies currently under investigation for MM, and appropriately discuss clinical trial participation with eligible patients.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY
To be announced.

MODERATOR
To be announced.

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Bristol Myers Squibb.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom A/B — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.